These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

199 related articles for article (PubMed ID: 26698305)

  • 1. Revealing Different Roles of the mTOR-Targets S6K1 and S6K2 in Breast Cancer by Expression Profiling and Structural Analysis.
    Karlsson E; Magić I; Bostner J; Dyrager C; Lysholm F; Hallbeck AL; Stål O; Lundström P
    PLoS One; 2015; 10(12):e0145013. PubMed ID: 26698305
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The mTOR effectors 4EBP1 and S6K2 are frequently coexpressed, and associated with a poor prognosis and endocrine resistance in breast cancer: a retrospective study including patients from the randomised Stockholm tamoxifen trials.
    Karlsson E; Pérez-Tenorio G; Amin R; Bostner J; Skoog L; Fornander T; Sgroi DC; Nordenskjöld B; Hallbeck AL; Stål O
    Breast Cancer Res; 2013; 15(5):R96. PubMed ID: 24131622
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Distinct Roles of mTOR Targets S6K1 and S6K2 in Breast Cancer.
    Sridharan S; Basu A
    Int J Mol Sci; 2020 Feb; 21(4):. PubMed ID: 32054043
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Clinical potential of the mTOR targets S6K1 and S6K2 in breast cancer.
    Pérez-Tenorio G; Karlsson E; Waltersson MA; Olsson B; Holmlund B; Nordenskjöld B; Fornander T; Skoog L; Stål O
    Breast Cancer Res Treat; 2011 Aug; 128(3):713-23. PubMed ID: 20953835
    [TBL] [Abstract][Full Text] [Related]  

  • 5. High-resolution genomic analysis of the 11q13 amplicon in breast cancers identifies synergy with 8p12 amplification, involving the mTOR targets S6K2 and 4EBP1.
    Karlsson E; Waltersson MA; Bostner J; Pérez-Tenorio G; Olsson B; Hallbeck AL; Stål O
    Genes Chromosomes Cancer; 2011 Oct; 50(10):775-87. PubMed ID: 21748818
    [TBL] [Abstract][Full Text] [Related]  

  • 6. S6 kinase 2 promotes breast cancer cell survival via Akt.
    Sridharan S; Basu A
    Cancer Res; 2011 Apr; 71(7):2590-9. PubMed ID: 21427355
    [TBL] [Abstract][Full Text] [Related]  

  • 7. S6 kinase signaling: tamoxifen response and prognostic indication in two breast cancer cohorts.
    Bostner J; Karlsson E; Eding CB; Perez-Tenorio G; Franzén H; Konstantinell A; Fornander T; Nordenskjöld B; Stål O
    Endocr Relat Cancer; 2015 Jun; 22(3):331-43. PubMed ID: 25972244
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Gene amplification of ribosomal protein S6 kinase-1 and -2 in gastric cancer.
    Yoshida S; Matsumoto K; Arao T; Taniguchi H; Goto I; Hanafusa T; Nishio K; Yamada Y
    Anticancer Res; 2013 Feb; 33(2):469-75. PubMed ID: 23393338
    [TBL] [Abstract][Full Text] [Related]  

  • 9. S6K1(-/-)/S6K2(-/-) mice exhibit perinatal lethality and rapamycin-sensitive 5'-terminal oligopyrimidine mRNA translation and reveal a mitogen-activated protein kinase-dependent S6 kinase pathway.
    Pende M; Um SH; Mieulet V; Sticker M; Goss VL; Mestan J; Mueller M; Fumagalli S; Kozma SC; Thomas G
    Mol Cell Biol; 2004 Apr; 24(8):3112-24. PubMed ID: 15060135
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Immunohistochemical analysis of S6K1 and S6K2 expression in human breast tumors.
    Savinska LO; Lyzogubov VV; Usenko VS; Ovcharenko GV; Gorbenko ON; Rodnin MV; Vudmaska MI; Pogribniy PV; Kyyamova RG; Panasyuk GG; Nemazanyy IO; Malets MS; Palchevskyy SS; Gout IT; Filonenko VV
    Eksp Onkol; 2004 Mar; 26(1):24-30. PubMed ID: 15112576
    [TBL] [Abstract][Full Text] [Related]  

  • 11. S6 kinase 2 is bound to chromatin-nuclear matrix cellular fractions and is able to phosphorylate histone H3 at threonine 45 in vitro and in vivo.
    Ismail HM; Hurd PJ; Khalil MI; Kouzarides T; Bannister A; Gout I
    J Cell Biochem; 2014 Jun; 115(6):1048-62. PubMed ID: 23564320
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunohistochemical analysis of S6K1 and S6K2 localization in human breast tumors.
    Filonenko VV; Tytarenko R; Azatjan SK; Savinska LO; Gaydar YA; Gout IT; Usenko VS; Lyzogubov VV
    Exp Oncol; 2004 Dec; 26(4):294-9. PubMed ID: 15627062
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Immunohistochemical analysis of S6K1 and S6K2 expression in endometrial adenocarcinomas.
    Lyzogubov VV; Lytvyn DI; Dudchenko TM; Lubchenko NV; Pogrybniy PV; Nespryadko SV; Vinnitska AB; Usenko VS; Gout IT; Filonenko VV
    Exp Oncol; 2004 Dec; 26(4):287-93. PubMed ID: 15627061
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential expression of S6K2 dictates tissue-specific requirement for S6K1 in mediating aberrant mTORC1 signaling and tumorigenesis.
    Nardella C; Lunardi A; Fedele G; Clohessy JG; Alimonti A; Kozma SC; Thomas G; Loda M; Pandolfi PP
    Cancer Res; 2011 May; 71(10):3669-75. PubMed ID: 21444676
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mutational analysis of ribosomal S6 kinase 2 shows differential regulation of its kinase activity from that of ribosomal S6 kinase 1.
    Phin S; Kupferwasser D; Lam J; Lee-Fruman KK
    Biochem J; 2003 Jul; 373(Pt 2):583-91. PubMed ID: 12713446
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Trastuzumab stimulation of ribosomal protein S6 kinase 1 (S6K1) predicts de novo trastuzumab resistance.
    Huynh FC; Nguyen D; Jones FE
    Biochem Biophys Res Commun; 2017 Jan; 483(1):739-744. PubMed ID: 27993682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. S6K2 promises an important therapeutic potential for cancer.
    Sever Nİ; Cengiz Şahin S
    Future Oncol; 2019 Jan; 15(1):95-102. PubMed ID: 30730779
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Regulation of ribosomal S6 kinase 2 by effectors of the phosphoinositide 3-kinase pathway.
    Martin KA; Schalm SS; Richardson C; Romanelli A; Keon KL; Blenis J
    J Biol Chem; 2001 Mar; 276(11):7884-91. PubMed ID: 11108711
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Characterization of S6K2, a novel kinase homologous to S6K1.
    Lee-Fruman KK; Kuo CJ; Lippincott J; Terada N; Blenis J
    Oncogene; 1999 Sep; 18(36):5108-14. PubMed ID: 10490847
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Silencing the FOLR2 Gene Inhibits Cell Proliferation and Increases Apoptosis in the NCI-H1650 Non-Small Cell Lung Cancer Cell Line via Inhibition of AKT/Mammalian Target of Rapamycin (mTOR)/Ribosomal Protein S6 Kinase 1 (S6K1) Signaling.
    Xu X; Jiang J; Yao L; Ji B
    Med Sci Monit; 2018 Nov; 24():8064-8073. PubMed ID: 30415267
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.